Baseline characteristics according to type of HCT
| Characteristics . | Allo-HCT (n =118) . | Auto-HCT (n =53) . |
|---|---|---|
| Age, median (range), y | 61 (26-73) | 65 (30-79) |
| Males | 81 (69) | 37 (70) |
| White race | 96 (81) | 47 (89) |
| KPS | ||
| ≥90 | 69 (58) | 28 (53) |
| Missing | 2 (2) | 1 (2) |
| HCT-CI | ||
| 3+ | 41 (35) | 32 (60) |
| Missing | 8 (7) | 2 (4) |
| Prior auto-HCT | 4 (3) | N/A |
| Cytogenetic abnormalities | ||
| 17p ± others | 39 (33) | 4 (7) |
| 11q deletion ± others (except 17p) | 10 (9) | 0 |
| Trisomy 12 ± others (except 17p and/or 11q) | 13 (11) | 3 (6) |
| None | 13 (11) | 13 (24) |
| Deletion of 13q alone | 4 (3) | 6 (11) |
| Others | 15 (13) | 5 (9) |
| Missing | 24 (20) | 22 (42) |
| Received novel agents before HCT* | ||
| Bruton’s tyrosine kinase inhibitor | 45 (38) | 5 (9) |
| Venetoclax | 7 (6) | 0 |
| PI3K inhibitor | 6 (5) | 0 |
| None | 69 (59) | 46 (87) |
| Missing | 3 (2) | 2 (4) |
| Novel agent | ||
| Yes, before RS | 13 (11) | 2 (4) |
| Yes, after RS | 18 (15) | 3 (6) |
| Both | 15 (13) | 0 |
| Neither | 69 (58) | 46 (87) |
| Missing | 3 (3) | 2 (4) |
| Response to first line RS therapy | ||
| CR | 31 (26) | 24 (45) |
| PR | 25 (21) | 10 (19) |
| Refractory disease | 41 (35) | 8 (15) |
| Not assessed | 21 (18) | 11 (21) |
| Prior therapy regimens received for CLL/SLL before RS, median (range), n | 2 (1-10) | 2 (1-5) |
| Prior therapy regimens received for RS, median (range), n | 2 (1-8) | 2 (1-6) |
| Time from CLL diagnosis to RS, median (range), mo | 30 (0-296) | 32 (0-166) |
| Characteristics . | Allo-HCT (n =118) . | Auto-HCT (n =53) . |
|---|---|---|
| Age, median (range), y | 61 (26-73) | 65 (30-79) |
| Males | 81 (69) | 37 (70) |
| White race | 96 (81) | 47 (89) |
| KPS | ||
| ≥90 | 69 (58) | 28 (53) |
| Missing | 2 (2) | 1 (2) |
| HCT-CI | ||
| 3+ | 41 (35) | 32 (60) |
| Missing | 8 (7) | 2 (4) |
| Prior auto-HCT | 4 (3) | N/A |
| Cytogenetic abnormalities | ||
| 17p ± others | 39 (33) | 4 (7) |
| 11q deletion ± others (except 17p) | 10 (9) | 0 |
| Trisomy 12 ± others (except 17p and/or 11q) | 13 (11) | 3 (6) |
| None | 13 (11) | 13 (24) |
| Deletion of 13q alone | 4 (3) | 6 (11) |
| Others | 15 (13) | 5 (9) |
| Missing | 24 (20) | 22 (42) |
| Received novel agents before HCT* | ||
| Bruton’s tyrosine kinase inhibitor | 45 (38) | 5 (9) |
| Venetoclax | 7 (6) | 0 |
| PI3K inhibitor | 6 (5) | 0 |
| None | 69 (59) | 46 (87) |
| Missing | 3 (2) | 2 (4) |
| Novel agent | ||
| Yes, before RS | 13 (11) | 2 (4) |
| Yes, after RS | 18 (15) | 3 (6) |
| Both | 15 (13) | 0 |
| Neither | 69 (58) | 46 (87) |
| Missing | 3 (3) | 2 (4) |
| Response to first line RS therapy | ||
| CR | 31 (26) | 24 (45) |
| PR | 25 (21) | 10 (19) |
| Refractory disease | 41 (35) | 8 (15) |
| Not assessed | 21 (18) | 11 (21) |
| Prior therapy regimens received for CLL/SLL before RS, median (range), n | 2 (1-10) | 2 (1-5) |
| Prior therapy regimens received for RS, median (range), n | 2 (1-8) | 2 (1-6) |
| Time from CLL diagnosis to RS, median (range), mo | 30 (0-296) | 32 (0-166) |
Unless otherwise indicated, data are n (%).
HCT-CI, HCT Comorbidity Index; IGHV, immunoglobulin variable region heavy chain, PI3K, phosphatidylinositol 3-kinase; PS, Karnofsky Performance Status; ±, with or without.
Total adds up to 130 rather than 118 because some patients received >1 type of novel therapy.